Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Sponsor
West China Hospital
Study ID
NCT06482086
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Locally Advanced Thyroid Gland Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Anlotinib — DRUG
    8/10/12 mg qd, po. Stop the medication for one week after taking it for two weeks.
  • Lenvatinib — DRUG
    8/12 mg qd, po.
  • Sorafenib — DRUG
    0.4 g bid, po.
  • Donafenib — DRUG
    0.3 g bid, po.
  • Everolimus — DRUG
    10 mg qd, po.
  • Apatinib — DRUG
    500 mg qd, po.
  • Dabrafenib + Trametinib — DRUG
    Dabrafenib 150 mg bid, po+Trametinib 2 mg qd, po.
  • Cabozantinib — DRUG
    Cabozantinib 60mg qd, po.
  • Vandetanib — DRUG
    Vandetanib 300mg qd, po.
  • Entrectinib — DRUG
    Entrectinib 600mg qd，po.
  • Pralsetinib — DRUG
    400mg qd, po.
  • Larotrectinib — DRUG
    100mg qd，po

Study Details

The current study aims to explore the potential advantages of anti-cancer therapy that is implemented based on drug sensitivity testing. This pertains to individuals with locally advanced thyroid cancer who have undergone conventional therapy in the past or unresectable patients .

Key Dates

Start date
Jun 1, 2021
Status verified
Dec 2024
Primary completion
Dec 1, 2024
Completion
Dec 1, 2025

Study Design

Enrollment
75 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Organoid-guided targeted therapeutic group
    Patients who take the recommended drugs regularly based on sensitivity analysis.

Primary Outcome Measure

Objective response rate [ Time Frame: Every 8 weeks until progression up to 3 years ]

Central Contacts